Prediction of drug –drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling

ConclusionsThis PBPK model accurately described the observed PK profiles of dasatinib. The validated PBPK model predicts low risk of clinically significant DDIs between dasatinib and metformin, pravastatin, or rosuvastatin.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research